MX2022007573A - Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b. - Google Patents
Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b.Info
- Publication number
- MX2022007573A MX2022007573A MX2022007573A MX2022007573A MX2022007573A MX 2022007573 A MX2022007573 A MX 2022007573A MX 2022007573 A MX2022007573 A MX 2022007573A MX 2022007573 A MX2022007573 A MX 2022007573A MX 2022007573 A MX2022007573 A MX 2022007573A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- combination therapy
- adenosine receptor
- disclosed
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se describen terapias de combinación que comprenden la administración de un inhibidor de CD73 y un inhibidor del receptor de adenosina A2A o A2B. Las terapias de combinación descritas son útiles en el tratamiento de enfermedades relacionadas con la actividad de los receptores de adenosina y/o CD73 que incluyen, por ejemplo, cáncer, enfermedades inflamatorias, enfermedades cardiovasculares y enfermedades neurodegenerativas. También se describen anticuerpos anti-CD73 e inhibidores de A2A/A2B.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062956840P | 2020-01-03 | 2020-01-03 | |
PCT/US2020/067576 WO2021138498A1 (en) | 2020-01-03 | 2020-12-30 | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007573A true MX2022007573A (es) | 2022-09-23 |
Family
ID=74236306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007573A MX2022007573A (es) | 2020-01-03 | 2020-12-30 | Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210230294A1 (es) |
EP (1) | EP4084870A1 (es) |
JP (1) | JP2023509442A (es) |
KR (1) | KR20220137013A (es) |
CN (1) | CN115551595A (es) |
AU (1) | AU2020419293A1 (es) |
CA (1) | CA3166536A1 (es) |
CL (1) | CL2022001795A1 (es) |
IL (1) | IL294437A (es) |
MX (1) | MX2022007573A (es) |
TW (1) | TW202135823A (es) |
WO (1) | WO2021138498A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3135487A1 (en) * | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
WO2021247188A1 (en) * | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1637160A3 (en) | 1999-05-07 | 2006-05-03 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
CA2405632A1 (en) | 2000-04-25 | 2001-11-01 | Idec Pharmaceutical Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
DK1961767T3 (da) | 2001-01-17 | 2012-05-29 | Biosceptre Int Ltd | Diagnose og behandling af cancere og andre lidelser |
WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
NZ587776A (en) | 2003-04-09 | 2012-03-30 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody |
AU2004253868B2 (en) | 2003-06-13 | 2011-06-16 | Biogen Ma Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
KR20080025066A (ko) | 2005-05-18 | 2008-03-19 | 바이오겐 아이덱 인크. | 섬유성 상태의 치료 방법 |
EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
EP2347769A1 (en) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
MX2017004691A (es) | 2014-10-10 | 2017-10-02 | Innate Pharma | Bloqueo de cd73. |
US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
EP3789403A1 (en) * | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
MX2018006973A (es) | 2015-12-09 | 2019-05-16 | Corvus Pharmaceuticals Inc | Anticuerpos anti-cd73 humanizados. |
US10793636B2 (en) | 2016-07-11 | 2020-10-06 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibodies |
US11180554B2 (en) | 2016-12-13 | 2021-11-23 | Astellas Pharma Inc. | Anti-human CD73 antibody |
LT3383916T (lt) | 2017-01-24 | 2022-06-10 | I-Mab Biopharma Us Limited | Antikūnai prieš cd73 ir jų panaudojimo būdai |
WO2018187512A1 (en) | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
CA3063344A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Novel cd73 antibody, preparation and uses thereof |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
WO2019170131A1 (zh) | 2018-03-07 | 2019-09-12 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
KR20200128542A (ko) | 2018-03-09 | 2020-11-13 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd73 항체 및 이의 용도 |
CA3093468A1 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
MX2020012376A (es) * | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
US20210214459A1 (en) * | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
-
2020
- 2020-12-30 AU AU2020419293A patent/AU2020419293A1/en active Pending
- 2020-12-30 IL IL294437A patent/IL294437A/en unknown
- 2020-12-30 US US17/138,306 patent/US20210230294A1/en active Pending
- 2020-12-30 KR KR1020227026716A patent/KR20220137013A/ko unknown
- 2020-12-30 CA CA3166536A patent/CA3166536A1/en active Pending
- 2020-12-30 CN CN202080097404.0A patent/CN115551595A/zh active Pending
- 2020-12-30 TW TW109146858A patent/TW202135823A/zh unknown
- 2020-12-30 MX MX2022007573A patent/MX2022007573A/es unknown
- 2020-12-30 EP EP20845756.4A patent/EP4084870A1/en active Pending
- 2020-12-30 WO PCT/US2020/067576 patent/WO2021138498A1/en unknown
- 2020-12-30 JP JP2022540916A patent/JP2023509442A/ja active Pending
-
2022
- 2022-06-30 CL CL2022001795A patent/CL2022001795A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL294437A (en) | 2022-09-01 |
AU2020419293A1 (en) | 2022-07-28 |
EP4084870A1 (en) | 2022-11-09 |
WO2021138498A1 (en) | 2021-07-08 |
CN115551595A (zh) | 2022-12-30 |
US20210230294A1 (en) | 2021-07-29 |
JP2023509442A (ja) | 2023-03-08 |
CA3166536A1 (en) | 2021-07-08 |
CL2022001795A1 (es) | 2023-02-03 |
TW202135823A (zh) | 2021-10-01 |
KR20220137013A (ko) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551332A1 (en) | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors | |
JOP20210074A1 (ar) | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها | |
JOP20200342A1 (ar) | مشتقات بيرازين مدمجة كمثبطات a2a/a2b | |
PH12019501671A1 (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
MY180894A (en) | Methods for incresing efficacy of folr1 cancer therapy | |
CL2023001918A1 (es) | Terapia combinada que comprende inhibidores a2a/a2b, inhibidores pd-1/pd-l1 y anticuerpos anti-cd73. | |
MX2022007573A (es) | Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b. | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
RS20050802A (en) | Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis | |
MX2021002998A (es) | Compuestos de triazolo-pirimidina y usos de los mismos. | |
AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
MX2022002219A (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
MX2021009117A (es) | Pirazolopiridinas y triazolopiridinas como inhibidores receptores de adenosina a2a / a2b. | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
MX2019013862A (es) | Terapia de combinacion. | |
EA201992430A1 (ru) | Комбинированная терапия рака предстательной железы | |
UA86586C2 (ru) | Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
UA102258C2 (en) | Pharmaceutical combination | |
MX2021012931A (es) | Polipeptidos multiespecificos activables y terapeuticos con semivida extendida. | |
MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
WO2016191703A3 (en) | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer | |
WO2020092720A3 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
Skarbnik et al. | Preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab (I) and nivolumab (N) as consolidation following autologous stem cell transplantation (ASCT) for high-risk hematologic malignancies-Cpit-001 trial |